HPV infection and cervical lesions
Conditions
Interventions
Experimental group:Rebacin
Positive control group1:Recombinant human interferon a-2b
Positive control group2:Baofukang
Sponsors
Shengjing Hospital of China Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Non-pregnant and non-lactating women over the age of 18 years, those who have a sexual life; 2. Patients with high-risk HPV infection for more than 12 months were diagnosed as stage CINI with high-risk HPV infection (including compound subtype infection), after CINII/CINIII (conization or circumcision, and no lesion was found at the incisal margin), and persistent infection of high-risk HPV after operation of cervical cancer; 3. Those who agree to use effective contraception during the trial and prohibit sexual life during the treatment period; 4. Willing and guaranteed to collaborate in accordance with the requirements of the program.
Exclusion criteria
Exclusion criteria: 1. Allergic to experimental drugs; 2. Pregnant and lactating women; 3. The recurrent cases of cervical intraepithelial neoplasia after operation were CINII/CINIII, cervical cancer recurrence and cancer metastasis; 4. Patients with AIDS, lupus erythematosus, selective IgA deficiency, chronic lymphocytic leukemia, multiple myeloma, lymphoma and other malignant tumors; 5. Postoperative radiotherapy and chemotherapy for cervical cancer (within 2 years), or long-term use of corticosteroids and immunosuppressants and other immunosuppressive agents; 6. Patients with trichomonal, fungal and bacterial vaginosis; 7. Other experimental drugs were used within one month before being enrolled in this experiment; 8. Patients who are using antibiotics and cortisone; 9. Those who do not agree to participate in the trial and do not sign an informed consent form; 10. Can't follow up on time; 11. Severe heart, lung, liver and kidney dysfunction, the researchers believe that it is not appropriate to participate in this clinical trial of the disease subjects.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HPV cure rate;HPV efficiency;Reversal rate of cervical lesions; | — |
Countries
China
Contacts
Public ContactMin Wang
Shengjing Hospital of China Medical University
Outcome results
None listed